Rationale: Postmitotic cells, such as cardiomyocytes, seem to be particularly susceptible to proteotoxic stimuli, and large, proteinaceous deposits are characteristic of the desmin-related cardiomyopathies and crystallin cardiomyopathic diseases. Increased activity of protein clearance pathways in the cardiomyocyte, such as proteasomal degradation and autophagy, has proven to be beneficial in maintaining cellular and cardiac function in the face of multiple proteotoxic insults, holding open the possibility of targeting these processes for the development of effective therapeutics.
P
roteotoxicity is defined as an impairment of cellular function as a result of protein misfolding or aggregation. 1, 2 Although it probably occurs in most or all cells, its potential pathogenic implications are particularly relevant to postmitotic cell populations, such as those found in brain and heart. For example, many of the neurodegenerative diseases are characterized by the accumulation of misfolded and aggregated proteinaceous accumulations. [3] [4] [5] When these accumulations of misfolded protein occur largely in postmitotic cells, unless the cell can autonomously clear them through various protein quality control (PQC) pathways, such as the proteasome or autophagy, the aggregates can eventually impair normal cellular functions and lead to pathology. As such, protein aggregates are a hallmark of many diseases, including neurodegeneration, 6, 7 diabetes mellitus, 8, 9 cystic fibrosis, 10, 11 and, as we and others have shown, heart failure. 12, 13 Although these phenotypes have been well studied and the pathogenic mechanisms at least partially defined, effective therapeutic approaches have proven more elusive.
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Some of the first evidence for the importance of cardiac proteotoxicity was observed in desmin-related myopathy, a progressive myopathic disease culminating in skeletal muscle wasting, cardiomyopathy, and premature death.
14 Although multiple gene mutations can lead to this disease, the mutations in the intermediate filament protein desmin or its molecular chaperone, CryAB (αB-crystallin), have been most intensively studied. Mutations in these proteins render the filamentous desmin architecture unstable, and electron dense, granulofilamentous protein aggregates accumulate within the cytoplasm of cardiomyocytes. 15 On expressing mutated CryAB (CryAB R120G ) exclusively in cardiomyocytes of transgenic mice, we were able to assess the cardiac-specific effects.
of misfolded proteins within the cardiomyocytes. In the CryAB R120G hearts, these deficits led to mitochondrial dysfunction and declining cardiac function, resulting in death by heart failure at or before 7 months. 17 Restoring normal levels of a PQC pathway, such as autophagy, delayed both the onset of overt disease and increased the probability of survival over time. These improvements were accompanied by decreased protein aggregate levels and improved cardiac function. 20 In fact, by upregulating autophagy, we were able to clear or significantly reduce aggresomal aggregates, 21 decrease toxic preamyloid oligomer load, restore cardiac function, and prolong life. 20, 22 Pathological accumulation of misfolded proteins may occur by common or related pathways in diverse cell types and across different diseases. For example, the accumulation of large perinuclear aggregates, or aggresomes, is found in both the neurodegenerative disorders 23 and in certain types of heart failure where the underlying pathologies are amplified by proteotoxic stimuli. 24 This not only implies convergent pathogenic pathways across disease presentations but also suggests that therapeutic avenues capable of decreasing aggregate load, either by preventing their accumulation or increasing cell autonomous clearance, might work across the spectrum of proteotoxic disease phenotypes.
Modulating the different pathways that cells use for PQC is becoming a focus for developing new therapies in multiple diseases, including cancer and heart failure. 25, 26 However, our basic understanding of the system-wide communication networks that control these processes and talk to one another is woefully incomplete. Driven by these conceptual difficulties, we have devised and performed an unbiased total genomic screen to find novel genes that can prevent or clear protein aggregates in a model of cardiac proteotoxicity. Using CryAB R120G -expressing mouse cardiomyocytes as the substrate, we used an inhibitory RNA library approach by systematically infecting the cells with pools of short hairpin (sh) RNA lentivirus that provided multiple coverage of ≈16 000 mouse genes. 27, 28 The subsequent validation of a selected primary candidate identified novel interacting proteins that were able to significantly affect aggregate levels in the cardiomyocytes.
Methods

Neonatal Rat or Mouse Cardiomyocyte Isolation
Hearts were harvested from 1-to 1.5-day-old pups and incubated in 0.05% trypsin overnight at 4°C. On removal of trypsin, hearts were rinsed with ice-cold αMEM, and hearts were dissociated with 260 U per heart collagenase in αMEM for 40 minutes at 37°C. The solution was triturated to disperse cell clumps and passed through a 40-μm strainer. The homogenate was then centrifuged for 5 minutes at 1500 rpm and the pellet resuspended in αMEM containing 10% FBS and DNAse. A preplating step was done to selectively isolate cardiomyocytes from the cardiac fibroblasts. Ten milliliters of cell suspension was added to uncoated 10 cm 2 plates and incubated for 40 minutes at 37°C in a 5% CO 2 incubator. The medium was removed and transferred to a conical fermenter. Cells (1×10 4 ) were added to each well of a gelatin-coated clear-bottomed black 96-well plate. 
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Novelty and Significance
What Is Known?
• The process of cellular self-digestion, autophagy, is critical for normal cell function and is often altered in cardiovascular disease, but a complete understanding of how the cardiomyocyte clears large aggregates is lacking.
• Unbiased, total genome-wide screens are useful for identifying unknown and unexpected candidates that affect general cellular processes, such as autophagy.
What New Information Does This Article Contribute?
• We outline a coherent rationale and method for setting up and successfully executing an unbiased, genome-wide screen for identifying gene products that affect aggregated protein clearance in the cardiomyocyte.
• We validate the importance of one of the identified candidates, Jak1
(Janus kinase 1), in playing an unexpected role in aggregate clearance.
• We present a database identifying additional candidates for the process, providing the community with a resource for future experimentation.
As a result of disturbances in protein homeostasis emanating from a variety of stimuli, including disease, protein misfolding occurs and can result in the formation of proteinaceous aggregates. This cellular response is observed in many failing hearts, and the aggregates can be cleared by autophagy and clearing aggregated proteins can be beneficial. We developed a high-throughput, genome-wide screen using short hairpin RNA knockdown via lentivirus infection, to identify novel participants in cardiomyocyte clearance processes. Cardiomyocytes were first transfected with adenovirus carrying a mutated αB-crystallin, which causes desmin-related cardiomyopathy and is characterized by the accumulation of large, proteinaceous aggregates. The cells were subsequently transduced with lentivirus carrying short hairpin RNA that in aggregate provided knockdown of the total genome complement. The screen identified gene products that prevented aggregation when chronically challenged with a proteotoxic stimulus. Candidates were selected on the basis of the screen and its effectiveness demonstrated by validation of one of the candidates, Jak1, whose role in the process had not been previously known. Our data demonstrate the effectiveness of the general approach for studying aggregate formation and clearance and provide a source of candidates that materially affect the processes for future study. Figure 5E through 5G), NRVMs were transfected 20 hours after plating with 50 nmol/L scrambled siRNA or short inhibitory (si) Jak1 and transduced with adenovirus encoding wild-type CryAB (CryAB WT ) or mutant CryAB R120G 5 hours after transfection. Medium was changed 24 hours after transfection to DMEM 2% FBS (including 5 μmol/L AraC to inhibit fibroblast growth) and then left for 6 days (7 days in total) until measurement of lactate dehydrogenase release using the Roche Cytotoxicity Detection Kit Plus (LDH; #04-744-926-001). Absorbance was measured at and optical density of 492 nm. For determination of Jak1 signaling (see Figure 4C and 4D), p-Stat3 antibody and signal transducer and activator of transcription (Stat) antibody (Cell Signaling #9145 and #12640, respectively) were used.
Lentiviral Infection
shRNA constructs were transfected into HEK-293T cells for highthroughput lentivirus production. Lentiviruses (50 μL) were added to each well of 96-well plates 6 hours after plating. Lentiviruses were left in contact with cells overnight before rinsing cells with fresh 2% FBS in DMEM media. Cells were allowed to recover for 6 hours before adenovirus infection.
Adenoviral Infection
Adenovirus containing CryAB-tGFP (turbo green fluorescent protein) was added at a multiplicity of infection =10 in serum-free DMEM and infected for 2 hours. After 2 hours, media were removed and replenished with DMEM containing 2% FBS and 1× antibioticantimycotic solution. Cells were fixed 4 days after CryAB infection.
Alamar Blue Assay
To assess lentiviral transduction efficiency, we treated cells that were or were not infected with lentivirus with puromycin; cells infected with lentivirus should be protected from the drug because of the expression of a puromycin resistance gene. After emptying the well, 50 μL of 20% Alamar Blue was added to each well and incubated for 1 hour at 37°C. Alamar Blue fluorescence was measured on a Synergy II plate reader (λ ex =530 nm/25; λ em =590 nm/35)
Screening Protocol
Ninety-six well black clear-bottomed plates were precoated with gelatin and allowed to air dry. Primary neonatal mouse cardiomyocytes were plated at 1×10 4 cells well in 100 μL of 10% FBS in αMEM and allowed to attach for 5 hours. After 6 hours, 70 μL of media was removed and replaced with 50 μL lentivirus stock and infected overnight. For control wells, 50 μL of media or scrambled (no target) lentivirus was added. After the incubation, 50 μL was removed from each well and replaced with 100 μL 4% FBS DMEM, and the cells were allowed to recover for 5 hours. After 5 hours, 100 μL was removed and replaced with 100 μL of CryAB R120G -tGFP adenovirus in serum-free, antibiotic-free DMEM at a multiplicity of infection =10. Cells were incubated at 37°C for 2 hours, after which 100 μL of 4% FBS DMEM was added to halt the infection. At this point, 100 μL Torin 1 (1 μmol/L) was added to the appropriate control well. After 48 hours, 150 μL was removed from each well and replaced with 150 μL puromycin (2 μg/mL) in 2% FBS DMEM except for nonpuromycin-treated controls. Forty-eight hours later, wells were emptied, rinsed with PBS, and fixed with 100 μL 4% paraformaldehyde in PBS for 15 minutes. Wells were subsequently washed 2× with PBS and stored at 4°C until imaged.
Counterstaining and Imaging
After fixation, the plates were counterstained to identify cardiomyocytes and nuclei. Cells were permeabilized with 0.5% Triton X-100 in PBS (PBST) for 20 minutes followed by two, 10-minute washes with PBS. Cells were blocked with 3% BSA in PBST for 30 minutes at room temperature. Mouse troponin I (TnI) antibody (Millipore MAB1691) was added at 1:2000 in blocking solution for 1 hour. Antibody was removed, and the cells washed twice for 10 minutes with PBST, followed by incubation with 1:400 secondary antibody (donkey antimouse Alexa Fluor 586; Life Technologies A10037) for 1 hour at room temperature. Antibody was removed, and the cells washed twice for 10 minutes each with PBST. Cells were incubated with DAPI (1:2000 in PBS) for 10 minutes at room temperature. After 2 washes with PBS-Tris, plates were sealed and stored until imaged. Imaging was performed on the BioTek Cytation 3 at room temperature using an automated plate stacker. Sixteen images were acquired using a 10× air objective above the center of the well, avoiding the edge of the wells. Physical separation between images was 800 μm (vertical)×1100 μm (horizontal) in a 4×4 array. Images were acquired in 3 channels: DAPI (λ em =377 nm, λ ex =447 nm; LED power=10, integration time=100 ms, gain=6.3), GFP (λ em =469 nm, λ ex =525 nm; LED power=5, integration time=28 ms, gain=0), and RFP (λ em =531 nm, λ ex =593 nm; LED power=10, integration time=601 ms, gain=15.6).
Bioinformatics
In silico approaches were used to interrogate the candidate lists against database information of other known pathways. We applied a literature-driven network analysis to identify genes from our screen associated with proteotoxicity-associated pathways. The OMIM and EntrezGene databases were used to identify annotated proteotoxicity genes. We then extended those gene sets to related biological processes using ToppGene (PMID:19465376) and AltAnalyze (PMID:20513647). The network generated with AltAnalyze (NetPerspective interface) was based on ChIP-target interactions from the PAZAR database, protein-protein interactions from BIOGRID and pathway connections from the KEGG and WikiPathways for literature associated proteotoxicity genes and primary hits.
Results
The High-Throughput, Genome-Wide Screen
We used a genome-wide RNA knockdown approach to screen for gene products that affected aggregate formation in a cardiomyocyte model of proteotoxicity using adenovirus-driven expression of CryAB R120G . The screen is schematically outlined in Figure 1A . When cultured under suitable conditions, primary neonatal mouse cardiomyocytes are nondividing cells that beat spontaneously and synchronously, displaying well-defined sarcomeres. To detect aggregate formation that could be analyzed using high-throughput imaging techniques, we cloned a tGFP fusion tag onto either normal, wildtype (CryAB WT -tGFP) or mutant CryAB (CryAB R120G -tGFP) and created replication-deficient adenoviruses using the AdEasy system. Genetic knockdown was achieved using the MISSION RNAi shRNA library, version 1.0, targeted against the mouse genome. The initial sets of shRNA lentivirus for mouse and human were set up through the RNAi Consortium, an initiative between Harvard, Massachusetts Institute of Technology, Washington, and Columbia Universities. 27 These libraries were then made available commercially. Lentivirus shRNA screening has now been successfully performed in multiple cell lines and in primary cells as well. The library contains shRNAs targeting ≈16 000 genes, in which each gene transcript is targeted by 3 to 5 distinct shRNAs to achieve a measure of internal verification during the primary screen. These constructs were then used to create lentiviruses expressing each shRNA. In addition to the sequence encoding the hairpin, the lentivirus construct contains a puromycin resistance gene so that only those cells infected by the lentivirus will be viable after selection. To determine the infectivity of neonatal mouse cardiomyocytes, we used a nontargeted shRNA containing a scrambled DNA sequence. Cells were infected for 96 hours before measuring cell viability using Alamar Blue (ThermoFisher) staining, with untreated cells used as a control ( Figure 1B ). Puromycin treatment of uninfected cells resulted in 100% cell death, which was not affected by adenoviral infection using the CryAB R120G construct. On infection of shRNA, cell viability was largely preserved, indicating efficient cardiomyocyte infection by lentivirus. After puromycin treatment there was a small but significant (7%) decrease in cell viability in the presence of both adenovirus and lentivirus, suggesting that lentivirus infected 93% of the cell population ( Figure 1B ). Subsequently, we included puromycin treatment in our protocol to ensure that the uninfected cells were eliminated from the analyses.
To determine whether CryAB R120G expression could provide a robust signal for aggregation using a high-throughput imaging approach, we infected cardiomyocytes with the adenovirus constructs containing either CryAB We then undertook an automated, high-throughput screen using the primary cardiomyocytes that were infected with adenovirus carrying the aggregate reporter construct (CryAB R120 -tGFP). After optimizing the basic components needed for the Screen (Online Table I ), the cells were plated robotically into 225, 96-well, black bottomed, microwell plates as detailed in Methods. All dilutions, washes, incubations, and screenings were automated to reduce well-to-well and plate-to-plate variation. Each well was infected with shRNA lentivirus, the goal being at least 5-fold coverage for each transcript, and each well in each plate was sampled in 16 different locations to rule out localized effects (Figure 3 ). The RNAi Consortium shRNA library was designed to minimize off-target effects, and the redundancy of multiple shRNAs able to target different regions of each gene's transcript allows for internal validation. 27 For the initial screen, we pooled these multiple shRNA lentiviruses, such that 3 to 5 different shRNAs targeting different regions of the target gene were expressed in the cardiomyocytes simultaneously. After lentivirus infection, the cells were allowed to grow, selected for infection via puromycin resistance (Figure 1 and Methods), fixed and then stained with troponin I antibody for cardiomyocyte identification, and DAPI to identify nuclei when needed, with CryAB-positive aggregates detected via tGFP fluorescence. A hierarchal algorithm was used to quantify puncta, with the first iteration detecting the aggregates and the second iteration keeping only those aggregates over a red (troponin I containing) field (Figure 3 ). Imaging filters were set conservatively so that maximum signal:noise ratios were conserved between each plate. Each plate also contained a positive control that used the compound Torin 1, a mechanistic target of rapamycin inhibitor ( Figure 3B ), which potently induces autophagy at both the early (autophagosome formation) and late (lysosomal degradation) steps. 29 In test platings, Torin 1 produced a reliable reduction in CryAB aggregates by between 50% and 70% and was used as an internal positive control for each plate to score a hit event. A BioTek Cytation 3 was used for data acquisition and high-content imaging. This device was also equipped with a plate loading tower, allowing image acquisition to occur unattended on a continuous basis.
We set an initial threshold of 50% aggregate reduction (measured by area of aggregate/cardiomyocyte) for hit identification. The primary screen with the pooled library yielded 2433 hits. For initial validation, we separated the pooled clones into 3 to 5 lentiviruses containing single shRNA clones and infected the cardiomyocytes with these single clones. To pass validation, at least 1 clone had to reduce aggregate content by >50%. Analysis of the validation screen data yielded a total of 236 hits, constituting ≈1.5% of the genome (Online Table II ).
Off-target effects can be sequence dependent or independent. Sequence-independent effects can relate to generalized cellular responses (eg, overall decrease in metabolic rate), whereas sequence-dependent effects can occur as a result of mismatched silencing characteristics for the shRNAs: this was minimized by the design of the RNAi Consortium library but even so, for a genome-wide screen it has been estimated that hits scored as such on the basis of a single shRNA would consist of 3362 off-target effects with only 20 true positives. 30 However, this drops to only 9 off-target hits if 3 unique shRNAs against the same target mRNA are all positive. Our initial, postscreen validations therefore focused on those clones that scored positive for >1 to 2 shRNAs against a single target -driven aggregate formation in primary cardiomyocytes. A, High levels of either normal or mutant CryAB (αB-crystallin) expression were driven off of the cytomegalovirus promoter after the placement of the indicated construct into adenovirus. B, Quantification of the relative signal strengths resulting from either CryAB wild type (CryAB WT ) or CryAB R120G was determined using immunofluorescence detected as a result of tGFP (turbo green fluorescent protein) expression. C, Primary cardiomyocytes were plated at optimum densities for signal:noise generation, infected with either normal or mutant CryAB and the cells fixed and stained 3 to 4 d after infection. Cardiomyocytes were identified by immunofluorescent detection of troponin I (red) showing that >90% of the cardiomyocytes contained easily detectable (>4-fold cytoplasmic CryAB WT -tGFP signal) CryAB-positive aggregates. D, Using BioTek Cytation 3 software, the algorithm defined aggregated protein on the basis of predefined filters and encircled them, creating yellow masks. To ensure that measured aggregates were within cardiomyocytes as opposed to cardiac fibroblasts or endothelial contaminants, hierarchical detection was done using a cardiomyocyte-specific counterstain, troponin I (red), such that only those cells where green aggregates were associated with red signal (green-over-red hierarchy) were scored and measured.
transcript. This decreased the hits from 236 to 14, and these clones are identified in Online Table II. A literature-driven in silico network analysis was subsequently used to further prioritize identified screen targets. Using multiple pathway databases (Methods), we identified an expanded set of proteotoxicity-associated genes, based on the literature. This analysis included genes associated with protein degradation and protein misfolding. Combined with genes from our screen, we derived a network containing multiple known proteotoxic effectors that interacted with our primary hits ( Figure 4A) . A substantial number of the genes identified in the screen have reported physical interactions with known proteotoxicity genes, including 18 that physically interact with amyloid precursor protein, a known causative agent in Alzheimer disease. In addition, we used this method to identify gene clusters that were able to independently reduce proteotoxic inclusions in cardiomyocytes, but had no known links to protein degradation or proteotoxicity.
Although our in silico, literature-and gene ontology-based analyses identified many intriguing pathways ( Figure 4A ), additional filtering was necessary to reduce the candidate number to a manageable size for experimentally based, lowthroughput validation. Two criteria constituted this next filter: (1) minimal documentation of protein or pathway(s) actions in the heart, to enhance the potential novelty of the candidate and its impact in the cardiac system, and (2) the protein or pathway would be present in different cell types and conserved throughout evolution, pointing to its general importance. Jak1 (Janus kinase 1) satisfied all the criteria. Three separate shRNA lentivirus scored positive in the initial screen ( Figure 4B ) and reduced aggregated protein content by >75%, without affecting cell viability. Moreover, Jak1 has reported direct and indirect associations with 5 additional candidate genes ( Figure 4A ). This tyrosine kinase is part of the JAK/ STAT (signaling transducer and activator of transcription) signaling pathway, whose members are widely distributed throughout different cell types and organ systems. 31, 32 Jak1 is Figure 3 . Inhibitory RNA knockdown of specific genes leads to decreased aggregate load in cardiomyocytes. A, Each well in each multi-welled plate was sampled in 16 separate locations, and only those plates showing uniform cardiomyocyte density and aggregates were selected for further analyses. B, At least 1 well per plate was also treated with Torin 1 to induce autophagy and confirm that a lack of aggregates could be scored on the particular plate. C, Typical data for those infections scored as primary hits for clones able to decrease aggregate load in cardiomyocytes subjected to the proteotoxic stimulus of CryAB R120G expression. Arrows point to examples of regions that the algorithm scored as positive for aggregates. Shown is a plate of mixed cardiomyocytes and fibroblasts in which the Control panel was infected with Ad-CryAB R120G but empty lentivirus. Shown in the shRNA panels are similar wells: an example of a well scored as a hit is shown. Note the staining across the different sampled areas of the well (top) and a striking decrease in aggregate content (yellow staining). Cardiomyocytes are stained red (troponin I antibody) and nuclei blue (DAPI). CryAB indicates αB-crystallin; and tGFP, turbo green fluorescent protein. Figure 4 . Systems biology prioritization of proteotoxicity regulators and Jak1 (Janus kinase 1) signaling. We first used the OMIM and EntrezGene databases to identify proteotoxicity-annotated genes, and then extended the identified gene sets to related biological processes using ToppGene and AltAnalyze. AltAnalyze NetPerspective network combining proteotoxicity-related genes and primary hits with shared direct protein-protein (BIOGRID, gray lines), pathway (WikiPathways, KEGG, grey arrows) or transcriptional regulatory (PAZAR database, red arrows) was visualized. A, A large proportion of primary hits (red dots) have reported interactions with known proteotoxicity genes (blue dots), including 18, which interact with amyloid precursor protein (APP): APP interacting genes are highlighted with a yellow background. A side cluster emerged centered about Jak1 (shown). B, Jak1 knockdown resulted in >75% reduction in aggregates using 3 individual shRNAs directed at the same gene transcript, with no effect to cell viability. A side cluster emerged centered about Jak1 (shown). C, Neonatal rat ventricular myocytes (NRVMs) were transduced with adenovirus encoding either GFP-CryAB WT or GFPCryAB R120G or left untransduced (control; C). Five days after transduction, cells were harvested for protein extraction. A, Representative Western blots stained for p-Stat3 and Stat3. α-actinin was used as a loading control. D, p-Stat3 and Stat3 quantification. Data are presented as mean±SEM with n=5. CryAB indicates αB-crystallin; tGFP, turbo green fluorescent protein; and WT, wild type.
a membrane protein whose kinase activity targets STAT proteins that are subsequently translocated to the nucleus to target specific gene transcription. Although most intensively studied for their important roles in cytokine signaling, modulating the immune response and oncogenesis, mutations in the proteins present in this pathway, including Jak1, cause many different diseases 33, 34 and are responsible for numerous hepatocellular adenomas. 35 In addition, the pathway is evolutionarily conserved and functions in transducing extracellular stimuli to the transcriptional apparatus. 36 However, although Jak1 is expressed in both heart and muscle (GeneCard database), Jak1 role in normal and diseased cardiomyocytes is relatively unexplored. To determine whether CryAB expression had any direct effects on Jak1 signaling, NRVMs were transduced with adenovirus encoding either GFP-CryAB WT or GFPCryAB R120G or left untransduced. Five days after transduction, cells were harvested for protein extraction and a downstream target of Jak1 signaling, p-stat3 quantified (Figure 4 ). Wildtype expression was ≈1.7× that of CryAB R120G to see if simply overexpressing the protein at relatively high levels had an effect as well. Overexpression of neither the normal nor the mutant proteins led to a statistically significant increase in Jak signaling. We therefore chose to further validate the Jak1 effects on cardiomyocyte aggregate accumulation.
Multiple siRNAs were tested for their efficacy in decreasing Jak1 expression in the infected cardiomyocytes: we chose one that resulted in 75% to 80% knockdown at low micromolar concentrations ( Figure 5A ). siJak1 transfection efficiently reduced Jak1 protein as well ( Figure 5B), although reduction at the protein levels was somewhat diminished when the cultures were cotransfected with CryAB R120G adenovirus as well ( Figure 5C ). Despite the only partial knockdown, and as expected on the basis of the initial screening data, treatment of CryAB R120G -infected cultures showed efficient abrogation of aggregate accumulation ( Figure 5D ).
To determine the effects of Jak1 knockdown for longer periods, a similar set of experiments was performed, but the cells were allowed to remain in culture for a total of 7 days to see if aggregates would begin to accumulate again. The data show that siJak1 treatment was effective during this time period as well, with no aggregates apparent in the cultures ( Figure 5E and 5F). Importantly, cell toxicity was also significantly decreased at the end of the 7 days as well ( Figure 5G ).
To begin to gain some insight into the processes responsible for the observed decreased aggregate load as a result of decreased Jak activity, we asked whether either proteasomal or autophagic flux increased as a result of Jak1 inhibition. We first explored possible alterations in proteasomal activity by taking advantage of a well-defined fluorescent reporter construct capable of detecting proteasomal flux. 37, 38 This inverse reporter, GFPu, is ubiquitously degraded when the proteasome is active, but, on inhibition of proteasomal flux, GFP levels are conserved, and the fluorescent signal can be easily detected. We coinfected NRVMs with adenovirus containing Flag-tagged CryAB R120G and GFPu-containing adenovirus and subsequently transfected the cells with siRNA for Jak1 ( Figure 6 ). Infection with CryAB R120G significantly increased GFP accumulation, a result consistent with previous data showing that the proteotoxic environment decreased proteasomal flux (Figure 6A and 6B) . 39 siJak RNA transfection significantly reduced GFP levels, indicating that proteasomal flux was significantly increased in the cells, potentially impacting the accumulation of misfolded proteins and the subsequent aggregate formation and accumulation. siRNA transfection also decreased GFP in cultures that had not been transfected with CryAB
R120G
, indicating that decreasing Jak activity in a nonproteotoxic environment resulted in improved UPS performance as well. We also treated the cardiomyocytes for 15 hours with 250 nmol/L epoxomicin, a proteasome inhibitor. As expected, the GFP level was increased after this treatment. Jak1 knockdown only slightly decreased GFP levels after this treatment, but its effect did not reach statistical significance, confirming the effective inhibition of the proteasome with the drug (Figure 6 ).
Similarly, we explored whether the process of autophagy was affected by decreasing Jak1 activity, as we have shown that autophagic flux is decreased in CryAB R120G hearts, and this decrease is at least partially responsible for increased aggregate load. 20, 21 Increased autophagy can clear preexisting aggregates, 20 decreasing proteotoxic load and cell toxicity. Figure 6 . Proteasomal activity is enhanced after Jak1 (Janus kinase 1) knockdown. Neonatal rat ventricular myocytes (NRVMs) were coinfected with adenoviruses containing Flag CryAB R120G and GFPu (a proteasome activity reporter). The cells were then transfected with siJak1 or a scrambled short inhibitory RNA (scr siRNA) for 4 d and treated with the proteasome inhibitor epoxomicin for 15 h. At 5 days postinfection, the cells were collected. A, Immunofluorescence with the cardiomyocyte marker TnI (red). Nuclei were counterstained with DAPI (blue). B, The relative GFP (green fluorescent protein) level in cardiomyocytes was quantified using NIS elements software. Control cells (ctr) were transfected with GFPu adenovirus only. *P<0.05, **P<0.01. C, Western blot analysis of GFP expression level. GAPDH was used as a loading control. D, The Western blot was quantified. *P<0.05, **P<0.01. CryAB indicates αB-crystallin.
To determine whether Jak1 knockdown induces autophagy and, thus, reduces CryAB R120G -tGFP protein aggregate levels, we transfected NRVMs with a siRNA targeting Jak1 and subsequently infected them with an adenovirus encoding CryAB R120G -tGFP. Protein levels of p62 and LC3-II, which can indicate increased autophagy, were measured before and after treatment with the lysosomal inhibitor Bafilomycin A1, which is used to determine autophagic flux (Figure 7 ). Jak1 knockdown decreased CryAB R120G -tGFP and p62 protein levels, confirming lower aggregate content. LC3-II protein levels did not differ between scrambled siRNA-transfected and siJak1-transfected cells before and after Bafilomycin A1 treatment, suggesting that Jak1 knockdown did not affect autophagic flux. Taken together, the data in Figures 6 and 7 suggest that Jak1 knockdown reduces CryAB R120G aggregation primarily by the activation of proteasomal activity, presumably by preventing initial aggregate formation rather than by clearing preexisting aggregates through autophagy.
Discussion
Cardiomyocytes and therefore cardiac function and hemodynamics are uniquely sensitive to proteotoxic stimuli and subsequent protein aggregation. Although preventing misfolded protein accumulation is key to every cell's health and requires constant surveillance, postmitotic cells are at particular risk for proteotoxic insult. In the presence of accumulating misfolded proteins, mitotic cells can remove them through asymmetrical division, thus preferentially placing the aggregate load into 1 of the 2 daughter cells and effectively preserving 1 cell. 40 Postmitotic cells are unable to divide away the protein load, rendering the entire organ susceptible to proteotoxic insult. In this respect, cardiomyocytes are similar to neurons, 41 as they are both largely postmitotic cell populations in an essential organ. Thus, proteotoxic insults can be particularly damaging; loss of neurons or cardiomyocytes via cell death can lead to neurodegeneration and heart failure, respectively. As proliferation of adult cardiomyocytes 42, 43 and neurons 41 is rare, both cell types have developed sophisticated and inclusive PQC mechanisms. Although we have found that manipulation of autophagy can be particularly beneficial in our desmin-related cardiomyopathy and other proteotoxic models, 44 other aspects of PQC are affected during CryAB R120G disease as well. 45 Thus, we decided to cast our net as widely as possible and used a genome-wide scan using shRNA knockdown for any gene product that resulted in significant decreases in cardiomyocyte aggregate load. We used neonatal cardiomyocytes as they rapidly accumulate the proteotoxic aggregates (Figure 1 ), contain all PQC systems, and robustly tolerate infection with adenovirus containing the CryAB R120G construct. A potential limitation of the system is that, in the whole animal, proteotoxicity does not present until midadulthood, and thus, formally, the processes under study are not exactly mimicking the situation in vivo, particularly as we used NRVMs.
With the discovery and rapid utilization of shRNA for generalized genome-wide screens in Drosophila, Caenorhabditis, and Planaria, the stage was set for their utilization in mammals via infection. We think that the mouse is particularly well suited for the shRNA-based, high-throughput screening approach. The mouse is genetically accessible, and our ability to manipulate the genome renders it suitable for validating novel effectors of a particular gene or process using organ-specific or cell-type-specific substrates. If a well-designed screen can be implemented, new players in a particular process or new gene/drug therapeutics can be identified. For unambiguous verification, sophisticated phenotyping analyses are widely available for genetically modified mice as well so that organ function and interactions can also be subsequently defined.
During the development phase of the screen, we attempted to construct many stable cell lines expressing CryAB R120G -tGFP, but were unable to obtain stable aggregate production in nonquiescent cells, presumably because of asymmetrical cell division; that is, after their initial formation, the aggregates were selectively divided into a daughter cell, resulting in cultures that did not exhibit the aggregate phenotype to an extent where a satisfactory signal:noise ratio could be obtained. We eventually chose to use primary neonatal mouse cardiomyocytes. This choice was made for several reasons: (1) robustness of signal, (2) ease of reporter induction, and (3) ability to directly relate our findings to cardiac disease. The limitations of using primary cells include needing moderate numbers of mice and batch-to-batch variation. However, we were able to establish both external and internal controls on a plate by plate basis and all experimental wells were normalized to those controls, such that the normalized data from different plates could be compared.
With the virus infection protocols in place, we optimized the other relevant parameters to ensure that the screen was robust and reproducible and the data could be compared between plates and wells. This required optimizing parameters, such as plate format, cell number, timing of viral infection, false-negative minimization, fixation time, incubation parameters, and cardiomyocyte counterstaining (Online Table I ). However, while necessary to ensure high-quality assay data, a well-designed and operational high-throughput screen is, in our view, only one of the essential determinants for success. Rather, what dictates the screen's ultimate success is a well-designed plan for candidate nomination, validation, and follow-up experimentation. The experiments that need to be performed include: (1) a retest of the individual shRNAs in the initial pool that scores a hit in the first pass to eliminate false-positive and potential off-target effects, (2) assays designed to determine specificity, (3) bioinformatics-based in silico analyses to determine potentially interesting relationships and identify a limited number of genes for subsequent, low-throughput assays, and eventually (4) creation of animal models suitable for testing the candidates' efficacy in reversing aggregate formation along with the proteotoxic compromise in cardiac function.
The identification and subsequent validation of Jak1 as a protein able to modulate aggregate load was surprising and illustrates the power of an unbiased, genome-wide screen. Jak1 is well known as an important player in interleukin, interferon, colony-stimulating factors, hormones, and cytokine signaling, and altered Jak activity has been linked to many different cancers, such as acute myeloid leukemia 46 and solid organ malignancies. 47 The Jak/STAT pathway(s) remain the archetypal membrane-to-nuclear gene transcription paradigm, where Jak1 is associated at the membrane with a cytokine receptor and responds to receptor binding by activating its tyrosine kinase activity. Subsequently, it undergoes both autophosphorylation and phosphorylates the cytoplasmic tail of the receptor, making the associated site accessible for STAT docking. On docking, STAT is also phosphorylated, dimerizes, and is subsequently transposed in that form to the nucleus where transcription of specific gene targets is initiated.
Currently, >25 Jak inhibitors are being tested in different trials, highlighting the intense interest in these pathways as therapeutic targets and ruxolitinib, a Jak1/2 inhibitor, has been approved by the FDA for the treatment of myelofibrosis and polycythemia vera. 48 But there are, to our knowledge, no data that bear directly on the pathway's relationship to proteinaceous aggregate accumulation or clearance. Using the human chronic myeloid leukemia cell line K-562, an association between ruxolitinib treatment and enhanced autophagy as determined by light chain 3B-II puncta formation was recently documented. 49 We had previously shown in the CryAB R120G cardiomyopathic hearts that increased autophagy is sufficient to decrease aggregate load in both cell culture and the intact animal. 20, 21 Another study dealt with pathogenesis associated with α-synuclein accumulation. Accumulation of aggregated α-synuclein is a hallmark of Parkinson disease, an age-related neurodegenerative condition. Using a model of α-synuclein expression to induce neuroinflammation and neurodegeneration, it was found that AZD1480 treatment, which reduces STAT1/3 activation, effectively reduced both the inflammatory process and cell degeneration. 50 We have noted striking parallels in our model of CryAB R120G -induced heart failure and the neurodegenerative diseases and the fact that STAT1/3 can effectively prevent dopaminergic neuron degeneration in vivo in a model of α-synuclein overexpression, by suppressing pathogenic inflammatory responses and other pathogenic signaling, is intriguing, pointing the way toward undertaking a more comprehensive analysis of the potential role of these pathways in cardiac proteotoxicity as well. However, the effect of AZD1480 on Lewy body accumulations was not determined.
Although proteotoxicity is increasingly being recognized as an important pathogenic process in a variety of human diseases, we are only just beginning to understand its underpinnings and potential therapeutic targets. We think that a series of genome-wide, unbiased screens for candidates that affect these processes would be of considerable value for generating new hypotheses and uncovering unsuspected players in both defined and undefined pathways. This approach is currently underway; we are currently performing genome-wide overexpression of the mouse genome to determine which genes can be activated to reduce the accumulation of proteotoxic inclusions. Although these approaches cannot provide a mechanistic understanding of data, they do provide a basis for hypothesis generation and subsequent mechanistic studies. In this initial report, we have established and validated a screen and performed a preliminary analysis on one of the initial candidates. Our data point to the value of this approach as they uncovered JAK/STAT signaling as a potentially intersecting pathway in the heart. The data also offer a new group of potential candidates for others to study as well (Online Table II) .
In an attempt to begin to approach the mechanism by which a Jak pathway intersects with aggregate load, we asked whether the effects of Jak1 knockdown were mediated primarily at the early stages of aggregate accumulation, when misfolded proteins are targeted for proteasomal degradation, or at the later stages, when the large, granulofilamentous aggregates can only be cleared via autophagy or alternative clearance mechanisms as yet undefined, as they are too large to fit into the restricted bore of the proteasome. Because of the limited time in culture that is inherent in the primary cells, this screen could not distinguish between aggregate formation and clearance. Nor did it provide any mechanistic evidence of how Jak1 was intersecting with proteasomal or autophagic clearance of misfolded proteins or aggregates. However, our data do point to the upregulation of proteasomal flux via Jak1 inhibition, and, considering the nature of the cells used for the screen, this is not surprising. Although aggregates can form relatively quickly, 51, 52 the screen was performed in cells undergoing active aggregate formation rather than in a postaccumulation period ( Figure 1A) . Thus, although this particular screen could not distinguish between proteins that might function during the accumulation period rather than acting on aggregate clearance because of the relatively short times involved, we expected the screen would be biased toward the aggregate formation phases of the process. Thus, screening for factors that might enhance clearance will necessarily involve infection with the shRNA libraries after aggregate formation has occurred and primary cardiomyocytes are not suitable for such a screen. These alternative screens are in the active planning stages in the laboratory.
However, even with the current screen's limitation, we isolated many interesting and unexpected candidates. Experiments dealing with loss of function of the pathway in the heart and dosing CryAB R120G mice with Jak1 inhibitors under normal and proteotoxic conditions should provide some insights as to the precise mechanism by which Jak1 inhibition affects aggregate load in a proteotoxic environment.
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